Update on preventive therapy (prophylaxis) for hereditary angioedema

Area of Science:

• Immunology
• Hematology
• Pharmacology

Background:

• Hereditary angioedema (HAE) management has evolved over the last decade.
• Traditional prophylactic treatments like attenuated androgens and antifibrinolytics have limitations due to side effects.
• Acute HAE therapy options were historically limited.

Purpose of the Study:

• To review recent advancements in both prophylactic and acute treatment strategies for hereditary angioedema.
• To highlight the introduction of new therapeutic agents.
• To discuss the impact of these advancements on HAE patient care.

Main Methods:

• Review of current literature and clinical practice guidelines.
• Analysis of newly approved and emerging therapies for HAE.
• Discussion of the comparative efficacy and safety profiles of different treatment options.

Main Results:

• Prophylactic treatment landscape expanded with the addition of plasma-derived C1 inhibitor.
• Newer agents have been introduced for the acute management of HAE attacks.
• These advancements offer more effective and potentially safer treatment options.

Conclusions:

• The past decade has seen a revolution in hereditary angioedema treatment.
• Expanded options for both prophylaxis and acute therapy have significantly improved patient management.
• Further research continues to refine HAE treatment strategies.